CL2011000848A1 - Composicion de crema topica estable que comprende ozenoxacina y un excipiente farmaceuticamente adecuado y uso de la composicion para la erradicacion de infecciones nasofaringeas en portadores nasales asintomaticos, y para el tratamiento o prevencion de infecciones de la piel, del tracto genital, y enfermedades de transmision sexual. - Google Patents
Composicion de crema topica estable que comprende ozenoxacina y un excipiente farmaceuticamente adecuado y uso de la composicion para la erradicacion de infecciones nasofaringeas en portadores nasales asintomaticos, y para el tratamiento o prevencion de infecciones de la piel, del tracto genital, y enfermedades de transmision sexual.Info
- Publication number
- CL2011000848A1 CL2011000848A1 CL2011000848A CL2011000848A CL2011000848A1 CL 2011000848 A1 CL2011000848 A1 CL 2011000848A1 CL 2011000848 A CL2011000848 A CL 2011000848A CL 2011000848 A CL2011000848 A CL 2011000848A CL 2011000848 A1 CL2011000848 A1 CL 2011000848A1
- Authority
- CL
- Chile
- Prior art keywords
- infections
- composition
- ozenoxacin
- prevention
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- XPIJWUTXQAGSLK-UHFFFAOYSA-N ozenoxacin Chemical compound C1=C(C)C(NC)=NC=C1C1=CC=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1C XPIJWUTXQAGSLK-UHFFFAOYSA-N 0.000 title abstract 3
- 229950011011 ozenoxacin Drugs 0.000 title abstract 3
- 239000000546 pharmaceutical excipient Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 229940100611 topical cream Drugs 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title 2
- 208000019802 Sexually transmitted disease Diseases 0.000 title 1
- 239000000969 carrier Substances 0.000 title 1
- 230000008029 eradication Effects 0.000 title 1
- 210000005000 reproductive tract Anatomy 0.000 title 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000003995 emulsifying agent Substances 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 206010040872 skin infection Diseases 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 229940100615 topical ointment Drugs 0.000 abstract 1
- 239000001993 wax Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08166933A EP2177208A1 (en) | 2008-10-17 | 2008-10-17 | Pharmaceutical topical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011000848A1 true CL2011000848A1 (es) | 2012-03-30 |
Family
ID=40291273
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011000848A CL2011000848A1 (es) | 2008-10-17 | 2011-04-15 | Composicion de crema topica estable que comprende ozenoxacina y un excipiente farmaceuticamente adecuado y uso de la composicion para la erradicacion de infecciones nasofaringeas en portadores nasales asintomaticos, y para el tratamiento o prevencion de infecciones de la piel, del tracto genital, y enfermedades de transmision sexual. |
| CL2015002899A CL2015002899A1 (es) | 2008-10-17 | 2015-09-29 | Composición farmacéutica de ungüento topico estable y excipiente adecuado seleccionado a partir de cera blanca, parafina blanda blanca y mezclas de los mismos. (divisional de solicitud 848-2011). |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015002899A CL2015002899A1 (es) | 2008-10-17 | 2015-09-29 | Composición farmacéutica de ungüento topico estable y excipiente adecuado seleccionado a partir de cera blanca, parafina blanda blanca y mezclas de los mismos. (divisional de solicitud 848-2011). |
Country Status (23)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012028720A2 (pt) | 2010-05-10 | 2016-07-19 | Segetis Inc | alquil cetal ésteres com dispersantes e agentes deslizantes para partículas sólidas, métodos de fabricação e suas utilizações |
| US9458414B2 (en) | 2012-09-21 | 2016-10-04 | Gfbiochemicals Limited | Cleaning, surfactant, and personal care compositions |
| DE102013226507B4 (de) * | 2013-12-18 | 2022-05-05 | Ashland Industries Europe Gmbh | Konzentrat umfassend Ferulasäureethylester und Arylalkanol und dessen Verwendung |
| ES2661000T3 (es) | 2014-09-12 | 2018-03-27 | Antibiotx A/S | Uso antibacteriano de salicilanilidas halogenadas |
| WO2016129657A1 (ja) * | 2015-02-13 | 2016-08-18 | マルホ株式会社 | ピリドンカルボン酸系誘導体を含有する外用剤 |
| GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
| GB201604484D0 (en) | 2016-03-16 | 2016-04-27 | Antibiotx Aps And Københavns Uni University Of Copenhagen | Topical antibacterial compositions |
| JP7347915B2 (ja) * | 2016-04-28 | 2023-09-20 | マルホ株式会社 | 抗菌剤 |
| WO2018048042A1 (ko) * | 2016-09-12 | 2018-03-15 | 주식회사 가나씨앤에이치 | 글리세린 젖산 에스테르를 유효성분으로 하는 방부 및 항균용 외용제 조성물 |
| WO2018101443A1 (ja) * | 2016-12-01 | 2018-06-07 | マルホ株式会社 | 医療用皮膚外用剤 |
| US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
| CN113712913A (zh) * | 2020-05-25 | 2021-11-30 | 南京帝昌医药科技有限公司 | 一种奥泽沙星混悬滴眼液组合物 |
| US11724077B2 (en) * | 2021-07-28 | 2023-08-15 | Subhash Dhawan | Therapeutic swabs for treating upper respiratory infections |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04243827A (ja) * | 1991-01-25 | 1992-08-31 | Sumitomo Pharmaceut Co Ltd | プロスタグランジン誘導体含有溶解型軟膏剤 |
| JP3174590B2 (ja) * | 1991-04-04 | 2001-06-11 | テルモ株式会社 | ステロイド軟膏剤 |
| FR2728166A1 (fr) * | 1994-12-19 | 1996-06-21 | Oreal | Composition topique contenant un antagoniste de substance p |
| JP3162335B2 (ja) * | 1998-03-11 | 2001-04-25 | ユーナイテッド ネイションズ デベロップメント プログラム | 皮膚真菌感染症治療用の植物薬剤、その製造法と用途 |
| WO1999051588A1 (en) | 1998-04-06 | 1999-10-14 | Toyama Chemical Co., Ltd. | Quinolonecarboxylic acid derivatives or salts thereof |
| CA2376210A1 (en) * | 1999-06-08 | 2000-12-14 | Lorantis Limited | Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway |
| JP4293755B2 (ja) | 2001-03-26 | 2009-07-08 | 富山化学工業株式会社 | ピリドンカルボン酸系化合物を含有する皮膚外用剤 |
| JP4384402B2 (ja) | 2001-11-30 | 2009-12-16 | 富山化学工業株式会社 | デスフルオロピリドンカルボン酸系化合物を含有する水溶液剤およびその粉末化物並びにそれら製造方法 |
| JP4875979B2 (ja) | 2004-03-31 | 2012-02-15 | 富山化学工業株式会社 | 難溶性薬物の微粒子分散液およびその製造方法 |
| EP1698336A1 (en) * | 2005-03-01 | 2006-09-06 | Ferrer Internacional, S.A. | Antifungal compositions comprising Sertaconazole and either Hydrocortisone or an antibacterial agent |
| KR101245960B1 (ko) | 2005-08-01 | 2013-03-21 | 마루호 코 엘티디 | 피리돈카르복시산 유도체를 함유하는 로션제 |
| JP5112669B2 (ja) | 2005-09-30 | 2013-01-09 | 富山化学工業株式会社 | 難溶性薬物のナノ微粒子を含有する水性懸濁液剤 |
-
2008
- 2008-10-17 EP EP08166933A patent/EP2177208A1/en not_active Withdrawn
-
2009
- 2009-10-16 BR BRPI0920355A patent/BRPI0920355B8/pt not_active IP Right Cessation
- 2009-10-16 EP EP09736946.6A patent/EP2344130B9/en active Active
- 2009-10-16 CA CA2738384A patent/CA2738384C/en active Active
- 2009-10-16 DK DK09736946.6T patent/DK2344130T3/da active
- 2009-10-16 RU RU2011119764/15A patent/RU2478367C2/ru active
- 2009-10-16 WO PCT/EP2009/063625 patent/WO2010043717A2/en not_active Ceased
- 2009-10-16 CN CN2009801408602A patent/CN102186460B/zh active Active
- 2009-10-16 JP JP2011531512A patent/JP5509209B2/ja not_active Expired - Fee Related
- 2009-10-16 KR KR1020167003529A patent/KR20160025034A/ko not_active Ceased
- 2009-10-16 PT PT97369466T patent/PT2344130E/pt unknown
- 2009-10-16 US US13/124,403 patent/US9180200B2/en active Active
- 2009-10-16 ES ES09736946.6T patent/ES2437967T3/es active Active
- 2009-10-16 PL PL09736946T patent/PL2344130T3/pl unknown
- 2009-10-16 MX MX2013009409A patent/MX338029B/es unknown
- 2009-10-16 KR KR1020117008243A patent/KR101682256B1/ko active Active
- 2009-10-16 AU AU2009305360A patent/AU2009305360B2/en not_active Ceased
- 2009-10-16 CA CA2822167A patent/CA2822167C/en not_active Expired - Fee Related
- 2009-10-16 SI SI200930749T patent/SI2344130T1/sl unknown
- 2009-10-16 MX MX2011004052A patent/MX2011004052A/es active IP Right Grant
- 2009-10-16 EP EP12192559A patent/EP2570117A1/en not_active Withdrawn
- 2009-10-16 KR KR1020167026446A patent/KR20160116353A/ko not_active Ceased
- 2009-10-19 UY UY0001032187A patent/UY32187A/es active IP Right Grant
- 2009-10-19 TW TW098135341A patent/TWI504418B/zh not_active IP Right Cessation
- 2009-10-19 TW TW103134727A patent/TW201511779A/zh unknown
- 2009-10-19 AR ARP090104005A patent/AR073901A1/es unknown
-
2011
- 2011-04-15 CL CL2011000848A patent/CL2011000848A1/es unknown
-
2013
- 2013-12-03 CY CY20131101082T patent/CY1114838T1/el unknown
-
2014
- 2014-02-21 JP JP2014031852A patent/JP5873120B2/ja not_active Expired - Fee Related
- 2014-03-05 US US14/197,933 patent/US9399014B2/en active Active
- 2014-10-29 PH PH12014502425A patent/PH12014502425A1/en unknown
-
2015
- 2015-09-29 CL CL2015002899A patent/CL2015002899A1/es unknown
- 2015-10-14 US US14/882,818 patent/US20160030338A1/en not_active Abandoned
-
2016
- 2016-05-04 US US15/146,461 patent/US10022363B2/en active Active
-
2017
- 2017-07-11 NL NL300884C patent/NL300884I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011000848A1 (es) | Composicion de crema topica estable que comprende ozenoxacina y un excipiente farmaceuticamente adecuado y uso de la composicion para la erradicacion de infecciones nasofaringeas en portadores nasales asintomaticos, y para el tratamiento o prevencion de infecciones de la piel, del tracto genital, y enfermedades de transmision sexual. | |
| AR124134A2 (es) | Formulación de uso tópico para un inhibidor de jak | |
| MX362382B (es) | Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas. | |
| WO2010084115A3 (en) | Antiviral agents | |
| CL2013003016A1 (es) | Una composicion oftalmica topica para el tratamiento y/o la profilaxis de una infeccion producida por un microorganismo o un trastorno de al menos un tejido ocular, que comprende a) 0,01 a 10% de povidona yodada y b) un esteroide seleccionado de acetato de prednisolona, etabonato de loteprednol, difluprednato, entre otros, o bromfenaco. | |
| BR112015020118A2 (pt) | derivados de 2-aminopirimidina para o tratamento de infecções virais | |
| CL2012002126A1 (es) | Composicion farmaceutica topica que comprende 1`-{[5-(trifluorometil)furan-2-il]metil}espiro[furo[2,3-f][1,3]benzodioxol-7,3`-indol]-2`(1`h)-ona; y uso para tratar, una enfermedad o condicion tal como dolor neuropatico, dolor quirurgico, dolor por trauma, dolor de cabeza cronico, entre otras. | |
| WO2008116135A3 (en) | Topical formulations having enhanced bioavailability | |
| ECSP088504A (es) | Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos | |
| CL2008002228A1 (es) | Compuestos derivados de imidazopiridinonas, agonista de tlr7; procedimiento de preparacion; compuestos intermediarios; composiicon farmaceutica que los comprende; y uso en infecciones virales, bacterianas y fungicas. | |
| WO2010010470A3 (en) | Methods of administering topical antifungal formulations for the treatment of fungal infections | |
| GT201200158A (es) | Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para su uso como principio activo farmacéutico | |
| CL2008003326A1 (es) | Compuestos derivados de [(2r)-3-[2-(5-fluoro-4-pirimidinil)hidrazino]-3-oxopropil]hidroxiformamida, formas polimorficas 1, 2 y 3 de dichos compuestos; composicion farmaceutica; y su uso en el tratamiento de una enfermedad bacteriana del oido, sinusitis, infeccion del tracto respiratorio superior, entre otras. | |
| CL2012000446A1 (es) | Uso de una formulación vesicular tópica que comprende uno o más fosfolípidos y uno o más tensoactivos en una razón molar de 1:1 a 25:1 de fosfolípidos a tensoactivos, para el tratamiento de trastornos dermatosos inflamatorios. | |
| BR112014028069A2 (pt) | composição farmacêutica oftálmica, processo para a preparação de uma composição farmacêutica oftálmica, uso de uma composição farmacêutica oftálmica, e, método para a prevenção ou tratamento de uma infecção fúngica | |
| CL2007002862A1 (es) | Uso del factor de crecimiento epidermico (egf) para tratar neuropatia sensitivo-motora, dolorosa y manifestaciones de neuritis isquemicas; composicion farmaceutica que comprende egf; y uso de la composicion antes dicha. | |
| CL2008002466A1 (es) | Composicion farmaceutica topica anhidra que comprende un vasodilatador y un vehiculo aceptable; uso de la composicion anhidra topica en las areas genitales para obtener bienestar sexual mejorado. | |
| WO2010066346A3 (en) | Composition for the prevention and treatment of viral infections | |
| CL2010000524A1 (es) | Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales. | |
| BR112014010509A2 (pt) | sistema de dispensa vaginal osmoticamente ativo | |
| CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. | |
| SV2010003701A (es) | Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre | |
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| WO2009084036A3 (en) | Composition for treatment of viral infections | |
| CO6321156A2 (es) | Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual |